» Articles » PMID: 24374503

Targeting Glucose Metabolism in Patients with Cancer

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2013 Dec 31
PMID 24374503
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Nearly a century ago, Otto Warburg made the astute observation that the metabolic properties of cancer cells differ markedly from those of normal cells. Several decades passed before the concept of exploiting cancer cell metabolism came into clinical practice with the advent of chemotherapy, the underlying principle of which is to target rapidly dividing cells by interfering with critical processes that are all, on some level, driven by cell metabolism. Although chemotherapy can be quite effective, success rates are highly variable and the adverse effects associated with treatment often outweigh the benefits due to the fact that chemotherapy is indiscriminately cytotoxic against all rapidly dividing cells, cancerous or healthy. During the past several years, a more intricate understanding of cancer cell metabolism has permitted the development of targeted therapies that aim to specifically target cancer cells and spare healthy tissue by exploiting the altered metabolism of cancer cells. The identification of new metabolic targets and the subsequent development of small-molecule inhibitors of metabolic enzymes have demonstrated the utility and promise of targeting cancer cell metabolism as an anticancer strategy. This review summarizes recent advances in the identification and characterization of several metabolic enzymes as emerging anticancer targets.

Citing Articles

The role of metabolic reprogramming in immune escape of triple-negative breast cancer.

Bao R, Qu H, Li B, Cheng K, Miao Y, Wang J Front Immunol. 2024; 15:1424237.

PMID: 39192979 PMC: 11347331. DOI: 10.3389/fimmu.2024.1424237.


Inhibition of Distal Glycolytic Enzymes Suppresses Fibroblast Activation without Deleterious Bioenergetic Effects.

Turner E, Roda G, Londono P, Herrera J, Evans C, Rangarajan S Am J Respir Cell Mol Biol. 2024; 70(6):519-521.

PMID: 38819122 PMC: 11160416. DOI: 10.1165/rcmb.2023-0193LE.


Crosstalk between lipid metabolism and EMT: emerging mechanisms and cancer therapy.

Din Z, Cui B, Wang C, Zhang X, Mehmood A, Peng F Mol Cell Biochem. 2024; 480(1):103-118.

PMID: 38622439 DOI: 10.1007/s11010-024-04995-1.


The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor.

Yang Y, Li Z, Wang Y, Gao J, Meng Y, Wang S EMBO Mol Med. 2024; 16(4):885-903.

PMID: 38448544 PMC: 11018795. DOI: 10.1038/s44321-024-00051-z.


Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type.

Yao N, Hou Q, Liang Y, Cao X, Sun B, Wei L Cancer Biomark. 2023; 39(4):265-275.

PMID: 38108343 PMC: 11191476. DOI: 10.3233/CBM-230068.


References
1.
Meyer L, Miller F, ROWEN M, Bock G, RUTZKY J . Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid). Acta Haematol. 1950; 4(3):157-67. DOI: 10.1159/000203749. View

2.
Hitosugi T, Kang S, Vander Heiden M, Chung T, Elf S, Lythgoe K . Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009; 2(97):ra73. PMC: 2812789. DOI: 10.1126/scisignal.2000431. View

3.
Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

4.
Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R . The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008; 452(7184):230-3. DOI: 10.1038/nature06734. View

5.
Anastasiou D, Yu Y, Israelsen W, Jiang J, Boxer M, Hong B . Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012; 8(10):839-47. PMC: 3711671. DOI: 10.1038/nchembio.1060. View